Brain Organoid Gene Therapy Reaches First Patient in Pitt Hopkins Syndrome Trial
Mahzi Therapeutics has begun clinical testing of MZ-1866 for Pitt Hopkins syndrome, an experimental gene therapy developed & tested using human brain organoids, with the first patient dosed in a Phase 1/2 study. This marks the first investigational gene therapy trial specifically targeting Pitt Hopkins syndrome, a condition that currently has no approved disease-modifying treatments.
Pitt Hopkins syndrome is a rare neurodevelopmental condition caused by mutations in the TCF4 gene. It is estimated to affect roughly 1 in 34,000 to 41,000 individuals, corresponding to around 8,000 people in the United States. The disorder typically involves developmental delay, intellectual disability, autism, low muscle tone, problems with coordination, irregular breathing patterns, severe gastrointestinal complications, and sometimes epilepsy.
Mahzi’s program is also entering the clinic at a time when the FDA has formally moved to a single-pivotal-trial default, while explicitly inviting “confirmative evidence” such as mechanistic data, validated biomarkers, real-world analyses, and New Approach Methods (NAMs) including organoids and in-silico models.
MZ-1866 was developed in collaboration with the Muotri Lab at the University of California San Diego. The clinical study received support from the California Institute for Regenerative Medicine, a state agency that funds stem cell and gene therapy research.
UNITE is an open-label trial, so both investigators and participants know the treatment being given. It is designed primarily to evaluate safety and tolerability after a single dose. In addition to safety, researchers will explore potential effects on development, communication, cognition, and motor skills.
The trial will enroll about 12 participants across five sites in the United States, Israel, and Spain. The therapy is designed to deliver a functional copy of the TCF4 gene directly into the brain, aiming to address the genetic cause of the disorder rather than only its symptoms.
How it works
TCF4 is a gene that plays a central role in brain development. When it does not function properly, neurons may not develop or communicate as they should. MZ-1866 is designed as a gene replacement therapy for Pitt Hopkins, a condition caused by mutation in TCF4. In simple terms, this approach introduces a working version of the faulty gene into cells, with the goal of restoring more typical biological function.
The therapy uses an adeno-associated virus type 9, or AAV9, as a delivery vehicle. AAVs are commonly used in gene therapy because they can transport genetic material into cells without causing disease.
In this case, the virus has been engineered to carry TCF4 isoform B, a version of the gene that is among the longest and most abundant forms found in the brain. Once delivered, the inserted gene is expected to begin producing the TCF4 protein under the control of regulatory DNA elements known as E-box sequences, which help guide gene expression.
About Mahzi
Mahzi Therapeutics is a clinical-stage biotechnology company developing precision therapies for rare genetic neurodevelopmental disorders, working in partnership with patient organizations and academic collaborators. The company focuses on conditions with limited or no disease-modifying treatment options and aims to select and advance the most suitable therapeutic modality for each indication through a combination of internal expertise and external collaborations.
Topic: Next-Gen Tools
